Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-CYB pseudogene 13 (MTCYBP13) is classified as a **pseudogene**, specifically a non-coding copy of the mitochondrial cytochrome b gene (MT-CYB)[4]. Pseudogenes do not encode functional proteins and typically do not have biological activity, clinical significance, or roles in disease or therapeutic intervention. In contrast, the true MT-CYB gene encodes cytochrome b, a core protein of mitochondrial complex III with well-documented roles in cellular energy production and mitochondrial disorders[1][3][7][9]. There is no evidence that MTCYBP13 codes for a functional protein, is implicated in human disease, or serves as a therapeutic target[4]. Key clarification: - MTCYBP13 is not the same as the *MT-CYB* gene (mitochondrially encoded cytochrome b). MTCYBP13 is a **pseudogene** and therefore does not produce the cytochrome b protein or participate in electron transport, oxidative phosphorylation, or any known cellular process[4]. - There are **no drug interactions, clinical biomarkers, mechanisms of action, or safety considerations** reported for this pseudogene, and it should not be considered a candidate therapeutic target under current classifications. If you are seeking information on the **functional mitochondrial cytochrome b gene** (MT-CYB), which does play a key role in energy metabolism and mitochondrial disorders, please specify, as the distinction is critical for accurate biomedical data structuring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-CYB pseudogene 13 (MTCYBP13).